Leukocytoclastic vasculitis after <scp>COVID</scp> ‐19 vaccination
Ece Altun, Elif Kuzucular
Abstract
Leukocytoclastic vasculitis (LCV) is the vasculitis of small vessels. In this report, we describe a 38-year-old male patient who presented to our outpatient clinic with a 1-week history of rash on his lower extremities that had started 4 days after receiving the Pfizer-BioNTech SARS-CoV-2 vaccine. A diagnosis of LCV was made based on clinical and histopathological findings. The patient was treated with antihistamines and prednisolone, after which improvement was observed in the lesions. With this paper, we aim to raise awareness concerning the possibility of LCV development after COVID-19 vaccination.
Topics & Concepts
MedicineLeukocytoclastic vasculitisDermatologyPrednisoloneVasculitisCoronavirus disease 2019 (COVID-19)VaccinationRashOutpatient clinicSurgeryPathologyInternal medicineInfectious disease (medical specialty)DiseaseDermatological and COVID-19 studiesVasculitis and related conditionsInflammasome and immune disorders